David Coeffic

914 total citations
33 papers, 468 citations indexed

About

David Coeffic is a scholar working on Oncology, Cancer Research and Reproductive Medicine. According to data from OpenAlex, David Coeffic has authored 33 papers receiving a total of 468 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 15 papers in Cancer Research and 6 papers in Reproductive Medicine. Recurrent topics in David Coeffic's work include Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (12 papers). David Coeffic is often cited by papers focused on Cancer Treatment and Pharmacology (17 papers), Breast Cancer Treatment Studies (14 papers) and HER2/EGFR in Cancer Research (12 papers). David Coeffic collaborates with scholars based in France, Italy and Australia. David Coeffic's co-authors include Laurent Arnould, David Khayat, Bruno Coudert, Éric-Charles Antoine, Mario Campone, P. Chollet, Frank Priou, Joseph Gligorov, B. Weber and V. Trillet-Lenoir and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and The Lancet Oncology.

In The Last Decade

David Coeffic

33 papers receiving 453 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
David Coeffic France	12	311	180	116	60	51	33	468
Ettie Piura Israel	9	181 0.6×	61 0.3×	50 0.4×	202 3.4×	98 1.9×	13	383
Steve van Os United States	9	199 0.6×	138 0.8×	122 1.1×	64 1.1×	340 6.7×	15	612
Rossella Martinello Italy	13	431 1.4×	229 1.3×	91 0.8×	134 2.2×	210 4.1×	26	626
Shan Zheng China	13	271 0.9×	133 0.7×	25 0.2×	106 1.8×	103 2.0×	41	482
Paule Augereau France	11	224 0.7×	80 0.4×	24 0.2×	102 1.7×	133 2.6×	45	402
Seyran Yiğit Türkiye	14	181 0.6×	93 0.5×	62 0.5×	76 1.3×	84 1.6×	43	433
Jean-Pierre Ferrière France	14	362 1.2×	307 1.7×	79 0.7×	70 1.2×	63 1.2×	26	571
V. Diéras France	8	261 0.8×	84 0.5×	38 0.3×	53 0.9×	65 1.3×	25	321
A. Vindevoghel Belgium	10	647 2.1×	474 2.6×	40 0.3×	134 2.2×	88 1.7×	23	868
Hans M. Westgeest Netherlands	13	150 0.5×	94 0.5×	66 0.6×	108 1.8×	189 3.7×	48	423

Countries citing papers authored by David Coeffic

Since Specialization

Citations

This map shows the geographic impact of David Coeffic's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by David Coeffic with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites David Coeffic more than expected).

Fields of papers citing papers by David Coeffic

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by David Coeffic. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by David Coeffic. The network helps show where David Coeffic may publish in the future.

Co-authorship network of co-authors of David Coeffic

This figure shows the co-authorship network connecting the top 25 collaborators of David Coeffic. A scholar is included among the top collaborators of David Coeffic based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with David Coeffic. David Coeffic is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Saghatchian, Mahasti, Elsa Curtit, David Coeffic, Alain Flinois, & Christelle Lévy. (2020). Étude en vie réelle de la survie à 7 ans des patientes traitées avec trastuzumab pour un cancer du sein précoce HER2+. Bulletin du Cancer. 107(7-8). 745–755. 1 indexed citations

Rouge, Thibault De La Motte, M-A Mouret-Reynier, Bernard Asselain, et al.. (2020). 823P Extended follow-up of a real-world cohort of patients (pts) with BRCA mutation (BRCAm) relapsed epithelial ovarian cancer (EOC) receiving olaparib maintenance therapy: The GINECO RETROLA study. Annals of Oncology. 31. S621–S622. 1 indexed citations

Sorio, Roberto, C. Roemer-Bécuwe, Felix Hilpert, et al.. (2016). Safety and efficacy of single-agent bevacizumab-containing therapy in elderly patients with platinum-resistant recurrent ovarian cancer: Subgroup analysis of the randomised phase III AURELIA trial. Gynecologic Oncology. 144(1). 65–71. 22 indexed citations

Spano, Jean‐Philippe, Philippe Beuzeboc, David Coeffic, et al.. (2015). Long term HER2+ metastatic breast cancer survivors treated by trastuzumab: Results from the French cohort study LHORA. The Breast. 24(4). 376–383. 14 indexed citations

Coudert, Bruno, Jean‐Yves Pierga, Marie‐Ange Mouret‐Reynier, et al.. (2014). Use of [18F]-FDG PET to predict response to neoadjuvant trastuzumab and docetaxel in patients with HER2-positive breast cancer, and addition of bevacizumab to neoadjuvant trastuzumab and docetaxel in [18F]-FDG PET-predicted non-responders (AVATAXHER): an open-label, randomised phase 2 trial. The Lancet Oncology. 15(13). 1493–1502. 97 indexed citations

Alexandre, J., Chris Brown, David Coeffic, et al.. (2012). CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: experience of the GCIG CALYPSO trial. British Journal of Cancer. 106(4). 633–637. 27 indexed citations

Pérol, David, Anne‐Claire Hardy‐Bessard, David Coeffic, et al.. (2012). Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial. BMC Cancer. 12(1). 603–603. 22 indexed citations

Cochet, Alexandre, Khaldoun Kerrou, F. Cachin, et al.. (2012). An open-label randomized, multicenter, phase II study on neoadjuvant treatment with trastuzumab plus docetaxel versus trastuzumab plus docetaxel plus bevacizumab according to positron emission tomography (PET) value modification in patients with early stage HER2-positive breast cancer (AVATAXHER): Design description.. Journal of Clinical Oncology. 30(15_suppl). TPS646–TPS646. 1 indexed citations

Freyer, Gilles, Mario Campone, Julien Péron, et al.. (2011). Adjuvant docetaxel/cyclophosphamide in breast cancer patients over the age of 70: Results of an observational study. Critical Reviews in Oncology/Hematology. 80(3). 466–473. 28 indexed citations

10.

Kurtz, Jean‐Emmanuel, Agathe Bajard, Jean‐Paul Guastalla, et al.. (2011). Bevacizumab plus microtubule targeting agents in heavily pre-treated ovarian cancer patients: a retrospective study. Bulletin du Cancer. 98(9). E80–E89. 4 indexed citations

11.

Bachelot, Thomas, Agathe Bajard, Isabelle Ray‐Coquard, et al.. (2011). Final Results of ERASME-4: A Randomized Trial of First-Line Docetaxel plus either Capecitabine or Epirubicin for Metastatic Breast Cancer. Oncology. 80(3-4). 262–268. 12 indexed citations

12.

Guiu, Séverine, Laure Favier, Isabelle Van Praagh, et al.. (2010). Long-term follow-up of HER2-overexpressing stage II or III breast cancer treated by anthracycline-free neoadjuvant chemotherapy. Annals of Oncology. 22(2). 321–328. 17 indexed citations

13.

Ray-Coquard, Isabelle Laure, J. Provençal, Anne‐Claire Hardy‐Bessard, et al.. (2009). Can adjuvant homeopathy improve the control of post-chemotherapy emesis in breast cancer patients? Results of a randomized placebo-controlled trial. Journal of Clinical Oncology. 27(15_suppl). e20566–e20566. 1 indexed citations

14.

Coudert, Bruno, Rémy Largillier, Laurent Arnould, et al.. (2007). Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial. Journal of Clinical Oncology. 25(19). 2678–2684. 102 indexed citations

15.

Delozier, T., Jean‐Paul Guastalla, Alejandro Yovine, et al.. (2006). A phase II study of an oxaliplatin/vinorelbine/5-fluorouracil combination in patients with anthracycline-pretreated and taxane-pretreated metastatic breast cancer. Anti-Cancer Drugs. 17(9). 1067–1073. 12 indexed citations

16.

Page, E, David Assouline, Catherine Durand, et al.. (2006). Stage-related changes in functional capacity in Hodgkin’s disease: assessment by cardiopulmonary exercise testing before initiation of treatment. Annals of Hematology. 85(12). 857–861. 4 indexed citations

17.

Guinet, François, Denis Castaing, René Adam, et al.. (2001). Prospective Phase II Trial of Irinotecan, 5-Fluorouracil, and Leucovorin in Combination as Salvage Therapy for Advanced Colorectal Cancer. American Journal of Clinical Oncology. 24(1). 101–105. 21 indexed citations

18.

Khayat, David, Éric-Charles Antoine, & David Coeffic. (2000). Taxol in the Management of Cancers of the Breast and the Ovary. Cancer Investigation. 18(3). 242–260. 37 indexed citations

19.

Khayat, D., et al.. (1998). European experience with irinotecan plus fluorouracil/folinic acid or mitomycin.. PubMed. 12(8 Suppl 6). 64–7. 5 indexed citations

20.

Rixe, Olivier, David Coeffic, B. Orcel, et al.. (1997). A Phase II Study of Cisplatin, 5-Fluorouracil, Leucovorin, and Etoposide in Advanced Non-Small-Cell Lung Cancer. American Journal of Clinical Oncology. 20(2). 128–131. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact